Market Overview - The main funds in the Shanghai and Shenzhen markets experienced a net outflow of 69.47 billion yuan, with the Sci-Tech Innovation Board seeing a net outflow of 3.65 billion yuan [1] - A total of 251 stocks saw net inflows, while 333 stocks experienced net outflows [1] Sci-Tech Innovation Board Performance - On the Sci-Tech Innovation Board, 215 stocks rose, with one stock, Hangke Technology, hitting the daily limit, while 367 stocks fell [1] - The top three stocks with the highest net inflows were Yuntian Lifa (23.77 million yuan), Baijie Shenzhou (23.09 million yuan), and Daqian Energy (20.33 million yuan) [1] Continuous Fund Flow Analysis - There were 52 stocks with continuous net inflows for more than three trading days, with KHHW leading at nine consecutive days of inflow [1] - Conversely, 155 stocks had continuous net outflows, with ST Nuotai and Xuantai Pharmaceutical both experiencing 14 consecutive days of outflow [1] Top Fund Inflows - The top stocks by net inflow included: - Yuntian Lifa: 23.77 million yuan, 6.20% inflow rate, 6.38% increase [1] - Baijie Shenzhou: 23.09 million yuan, 9.56% inflow rate, 12.55% increase [1] - Daqian Energy: 20.33 million yuan, 16.32% inflow rate, 7.12% increase [1] Notable Outflows - The stock with the highest net outflow was SMIC, with a net outflow of 1.92 billion yuan and a 3.74% decrease [1] - Other significant outflows included Haiguang Information (864 million yuan) and Shijia Photon (382 million yuan) [1]

江苏诺泰澳赛诺生物制药股份有限公司 2025 年第一次临时股东会会议资料 二零二五年九月 2025 年第一次临时股东会会议资料目录 | 2025 年第一次临时股东会会议须知 | 2 | | --- | --- | | 2025 年第一次临时股东会会议议程 | 4 | | 议案一：关于变更会计师事务所的议案 | 6 | | 议案二：关于取消监事会、修订《公司章程》及其附件的议案 | 10 | | 议案三：关于制定、修订部分公司治理制度的议案 | 25 | | 附件一：江苏诺泰澳赛诺生物制药股份有限公司章程 | 26 | | 附件二：江苏诺泰澳赛诺生物制药股份有限公司股东会议事规则 | 77 | | 附件三：江苏诺泰澳赛诺生物制药股份有限公司董事会议事规则 | 91 | | 附件四：江苏诺泰澳赛诺生物制药股份有限公司累积投票制实施细则 | 100 | | 附件五：江苏诺泰澳赛诺生物制药股份有限公司关于防范控股股东、实际控制人及 | | | 其他关联方资金占用管理制度 104 | | | 附件六：江苏诺泰澳赛诺生物制药股份有限公司董事、高级管理人员薪酬管理制度 | | | 108 | | 证券代码：688076 证 ...

关于江苏诺泰澳赛诺生物制药股份有限公司 2025 年半年度持续督导跟踪报告 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市 规则》《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等有关法 律法规的要求，南京证券股份有限公司（以下简称"南京证券"或"保荐机构"） 作为江苏诺泰澳赛诺生物制药股份有限公司（以下简称"诺泰生物""上市公司" 或"公司"）持续督导工作的保荐机构，负责诺泰生物上市后的持续督导工作， 并出具本持续督导跟踪报告。 南京证券股份有限公司 | 序号 | 工作内容 | 持续督导情况 | | --- | --- | --- | | 1 | 建立健全并有效执行持续督导工作 制度，并针对具体的持续督导工作 | 保荐机构已建立并有效执行了持续督导工作 | | | 制定相应的工作计划。 | 制度，并制定了相应的工作计划。 | | | 根据中国证监会相关规定，在持续 | | | | 督导工作开始前，与上市公司或相 | 保荐机构已与诺泰生物签订保荐协议，该协 | | 2 | 关当事人签署持续督导协议，明确 | 议明确了双方在持续督导期间的权利和义 | | | 双方在持续督导期间 ...

Group 1: Company Performance - CanSino reported a revenue of 382 million yuan for the first half of 2025, a year-on-year increase of 26%, with a net loss of 13.49 million yuan, narrowing by 94.02% compared to a loss of 225 million yuan in the same period last year [1] - Wantai Bio disclosed a revenue of 844 million yuan, a year-on-year decrease of 38.25%, resulting in a net loss of 144 million yuan, indicating a shift from profit to loss due to market adjustments and government procurement impacts [2] - Jimin Health reported a revenue of 366 million yuan, a year-on-year decline of 21.30%, with a net loss of 52.70 million yuan, compared to a profit of 25.44 million yuan in the previous year [3] - ST Noratech achieved a revenue of approximately 1.048 billion yuan, a year-on-year increase of 26.07%, with a net profit of about 310 million yuan, reflecting a growth of 36.49% [5] Group 2: Market Trends and Insights - The vaccine industry is facing challenges such as intensified competition and insufficient demand, leading to performance pressure on several companies, including CanSino and Zhifei Biological [2] - Jimin Health's stock experienced a significant increase of 53.78% over a short period, indicating potential market overreaction and speculative trading [3][4] - The demand for peptide raw materials, particularly GLP-1 related products, has driven ST Noratech's performance, highlighting a strong market for specific pharmaceutical segments [5] Group 3: Shareholder Actions - TBP 3Doctors (HK) Limited plans to reduce its stake in Sanbo Brain Science by up to 6.09 million shares, representing 3% of the total share capital, which may signal a lack of confidence in the company's future prospects [6]

Group 1 - The chemical pharmaceutical sector increased by 2.53% on August 25, with Shutaishen leading the gains [1] - The Shanghai Composite Index closed at 3883.56, up 1.51%, while the Shenzhen Component Index closed at 12441.07, up 2.26% [1] - Notable gainers in the chemical pharmaceutical sector included: - Buzoushen (300204) with a closing price of 61.00, up 16.17% and a trading volume of 445,500 shares [1] - Haichen Pharmaceutical (300584) with a closing price of 58.95, up 13.61% and a trading volume of 217,200 shares [1] - Changshan Pharmaceutical (300255) with a closing price of 53.25, up 12.84% and a trading volume of 683,900 shares [1] Group 2 - The chemical pharmaceutical sector experienced a net outflow of 426 million yuan from institutional investors, while retail investors saw a net inflow of 509 million yuan [2] - The top stocks by net inflow from retail investors included: - Anglikang (002940) with a net inflow of 163 million yuan, representing 22.87% of its trading volume [3] - Haichen Pharmaceutical (300584) with a net inflow of 132 million yuan, representing 10.90% of its trading volume [3] - Lingkang Pharmaceutical (603669) with a net inflow of 64.68 million yuan, representing 37.53% of its trading volume [3]

Financial Performance - The company reported a total revenue of 1.048 billion yuan for the first half of 2025, representing a year-on-year increase of 26.07% [1] - The net profit attributable to shareholders reached 310 million yuan, up 36.49% year-on-year [1] - The gross margin improved to 69.57%, an increase of 3.35% compared to the previous year, while the net margin rose to 28.84%, up 3.48% [1] Quarterly Analysis - In Q2 2025, the total revenue was 483 million yuan, showing a slight increase of 1.47% year-on-year [1] - The net profit for Q2 was 157 million yuan, which marked a decline of 2.12% year-on-year [1] Key Financial Ratios - The company’s total expenses (selling, administrative, and financial) amounted to 240 million yuan, accounting for 22.93% of revenue, an increase of 15.93% year-on-year [1] - Earnings per share (EPS) increased to 0.99 yuan, reflecting a growth of 30.26% year-on-year [1] Asset and Liability Changes - Cash and cash equivalents increased by 21.88% to 677 million yuan, primarily due to the redemption of structured deposits [3] - Interest-bearing liabilities surged by 72.94% to 2.026 billion yuan, indicating a significant increase in debt [1][3] - Accounts receivable rose by 25.75% to 613 million yuan, attributed to increased sales revenue [3] Investment and Development - The company has seen a 78.5% increase in construction in progress, driven by multiple ongoing projects [3] - The intangible assets grew by 42.39% due to the capitalization of certain pharmaceutical products [5] Cash Flow Analysis - The net cash flow from operating activities increased by 59.33%, attributed to higher cash collections from customers [26] - The net cash flow from investing activities decreased by 8.52%, reflecting increased purchases of fixed assets [26] Market Position and Business Model - The company’s return on invested capital (ROIC) was reported at 11.52%, indicating average capital returns [28] - The business model relies heavily on capital expenditures, necessitating careful evaluation of the profitability of these investments [28] Fund Holdings - The largest fund holding in the company is the "招商蓝筹精选股票A," which has increased its position, currently holding 2.7458 million shares [28]

Core Viewpoint - ST诺泰 (688076.SH) reported strong financial performance in the first half of 2025, driven by high demand for peptide raw materials, with revenue increasing by 26.07% to 1.048 billion yuan and net profit rising by 36.49% to 310 million yuan [2] Group 1: Financial Performance - The company achieved a revenue of 1.048 billion yuan, reflecting a year-on-year growth of 26.07% [2] - The net profit attributable to shareholders reached 310 million yuan, marking a 36.49% increase compared to the previous year [2] - The non-recurring net profit was reported at 306 million yuan, up by 33.49% year-on-year [2] Group 2: Market Expansion and Strategic Collaborations - The company has expanded its market presence in traditional markets like Europe and the U.S., while also covering emerging markets in Latin America and Asia-Pacific [3] - Strategic collaborations with leading generic drug companies have been established for projects involving semaglutide and teriparatide raw materials [3] - The company is building a second growth curve by leveraging platform strategies in emerging business sectors like oligonucleotides and conjugates [3] Group 3: Capacity Expansion - The company’s Lianyungang factory has launched a fourth-generation large-scale peptide production workshop, achieving an annual production capacity of 5 tons [4] - The newly established Jian’de factory has added 220,000 liters of GMP-grade product capacity with two multifunctional synthesis workshops and two D-grade clean areas [4] - The company is expected to complete the construction of its oligonucleotide commercial production workshop by October 2025, with an annual capacity of 1,000 kg for oligonucleotides and 200 kg for PEG-conjugated cyclic peptides [4] Group 4: R&D and Technological Advancements - The company is actively investing in cutting-edge technologies and has formed strategic partnerships to enhance its R&D capabilities [5] - A strategic cooperation agreement was signed with a leading company in biological manufacturing to advance synthetic biology technology [5] - The company aims to integrate AI technology into drug development, optimizing operations and building a comprehensive AI-driven pharmaceutical system [6] Group 5: Workforce and Innovation - The number of R&D personnel has reached 459, a 42% increase year-on-year, with 47% holding master's or doctoral degrees [6] - The company is focusing on interdisciplinary advantages to enhance its competitive edge in technology R&D and innovation [6] - Investments in various advanced technologies, including synthetic biology and AI-driven chemical processes, are expected to support the company's long-term sustainable development [6]

Core Viewpoint - The company, Nuotai Biotech, reported strong financial performance in the first half of 2025, driven by high demand for peptide raw materials, with a revenue increase of 26.07% year-on-year, reaching 1.048 billion yuan, and a net profit growth of 36.49%, amounting to 310 million yuan [1] Group 1: Financial Performance - The company's revenue for the first half of 2025 was 1.048 billion yuan, reflecting a year-on-year growth of 26.07% [1] - The net profit attributable to shareholders reached 310 million yuan, showing a year-on-year increase of 36.49% [1] - The non-recurring net profit was 306 million yuan, with a year-on-year growth of 33.49% [1] Group 2: Market Expansion and Strategic Collaborations - The company has established a strong foundation in the peptide raw material market, expanding into emerging markets in Latin America and Asia-Pacific while maintaining a presence in traditional markets [2] - Collaborations with leading generic drug companies on projects involving semaglutide and teriparatide have been initiated, contributing to the development of a second growth curve [2] - A comprehensive strategic partnership with DeepMind Technology focuses on AI technology to transform the biopharmaceutical industry, aiming to reshape drug development and manufacturing processes [5] Group 3: Capacity Expansion - The company’s Lianyungang factory has launched a new large-scale peptide production workshop with an annual capacity of 5 tons [3] - The newly established JianDe factory in Zhejiang has added 220,000 liters of GMP-grade product capacity [3] - The company is expected to complete the construction of a commercial production workshop for oligonucleotides by October 2025, with an annual capacity of 1,000 kg for oligonucleotides, 100 kg for PMO, and 200 kg for PEG-conjugated cyclic peptides [3] Group 4: R&D and Technological Advancements - The company is actively investing in cutting-edge technologies, including synthetic biology and AI-enabled drug development, to broaden its business scope [4] - A strategic partnership with Novozymes aims to leverage both companies' technological strengths in synthetic biology for innovative breakthroughs [4] - The company has increased its R&D personnel to 459, a 42% year-on-year growth, with 47% holding master's or doctoral degrees, enhancing its competitive edge in technology development [5]

Financial Performance - The company's total revenue for the first half of 2025 reached 1.048 billion yuan, an increase of 217 million yuan compared to the same period last year, marking a 26.07% year-on-year growth, achieving three consecutive years of increase [1] - The net profit attributable to shareholders was 310 million yuan, up by 82.886 million yuan from the same period last year, representing a 36.49% year-on-year increase, also achieving three consecutive years of growth [1] - The net cash inflow from operating activities was 316 million yuan, an increase of 118 million yuan compared to the same period last year, reflecting a 59.33% year-on-year growth, continuing a three-year upward trend [1] Profitability and Efficiency - The latest asset-liability ratio stands at 49.53% [3] - The latest gross profit margin is 69.57%, an increase of 2.25 percentage points from the same period last year, achieving three consecutive years of growth [3] - The latest return on equity (ROE) is 10.47%, up by 0.98 percentage points year-on-year [3] - The diluted earnings per share are 0.99 yuan, an increase of 0.23 yuan compared to the same period last year, representing a 30.26% year-on-year growth, also achieving three consecutive years of increase [3] - The latest total asset turnover ratio is 0.19 times, and the inventory turnover ratio is 0.49 times [3] Shareholder Information - The number of shareholders is 18,800, with the top ten shareholders holding 138 million shares, accounting for 43.87% of the total share capital [3]

公司最新总资产周转率为0.19次，较去年同期总资产周转率减少0.03次，同比较去年同期下降13.14%。 最新存货周转率为0.49次，较去年同期存货周转率减少0.18次，同比较去年同期下降26.59%。 公司股东户数为1.88万户，前十大股东持股数量为1.38亿股，占总股本比例为43.87%。 公司最新资产负债率为49.53%，较上季度资产负债率增加1.68个百分点，较去年同期资产负债率增加 9.82个百分点。 2025年8月21日，ST诺泰(688076.SH)发布2025年中报。 公司最新毛利率为69.57%，较上季度毛利率减少0.64个百分点。最新ROE为10.47%。 公司营业总收入为10.48亿元。归母净利润为3.10亿元。经营活动现金净流入为3.16亿元。 公司摊薄每股收益为0.99元。 ...